Introduction

Epinephrine is the first‑line, life‑saving treatment for anaphylaxis. In 2024, the U.S. Food and Drug Administration (FDA) approved the first non‑injection form—neffy (epinephrine nasal spray). In 2025, FDA expanded its use to younger children. This explainer clarifies what neffy is, how and when it’s used, how it compares with auto‑injectors, and how it relates to sublingual immunotherapy (SLIT) tablets and drops. Wyndly treats environmental allergies with SLIT and does not dispense or prescribe epinephrine products (including neffy).

What neffy is (regulatory status, ages/weights, dosing)

• Product: neffy (epinephrine nasal spray), a single‑dose intranasal form of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. Initial FDA approval: August 9, 2024, for adults and children ≥30 kg (≈66 lb). On March 7, 2025, FDA expanded the indication to children ≥4 years who weigh 15 to <30 kg (≈33 to <66 lb).

• Weight‑based doses per current U.S. labeling: 2 mg for patients ≥30 kg; 1 mg for patients 15 to <30 kg.

• Pharmacology/PK basis: Approval was supported by studies showing neffy produced epinephrine blood levels and cardiovascular effects comparable to approved injection products.

How to use neffy during a reaction (what patients are told in labeling)

• Use at the first signs of anaphylaxis. Administer 1 spray into one nostril (dose depends on weight). If there is no improvement or symptoms worsen, give a second dose using a new device in the same nostril starting 5 minutes after the first dose. Always seek emergency medical care after use. Carry two devices.

• Important limitation: Certain nasal conditions (e.g., nasal polyps, prior nasal surgery) may affect absorption; labeling advises discussing these with a clinician and considering an injectable epinephrine product. Common adverse effects include nasal/throat irritation, rhinorrhea, headache, jitteriness, and nausea.

How neffy compares with epinephrine auto‑injectors

• What’s similar: Both deliver the same medicine (epinephrine), are intended as first‑aid for anaphylaxis, may require a second dose, and require follow‑up emergency care.

• What’s different: Neffy is needle‑free and intranasal, which may reduce treatment delays due to needle aversion; however, intranasal absorption can be affected by nasal conditions, and current SLIT tablet labels (see below) specifically require prescribing an auto‑injectable epinephrine device.

• Availability and price context: U.S. retail launch began September 2024; some payers (e.g., Express Scripts) added neffy to commercial formularies in November 2024. Public reporting placed typical cash pricing for a two‑device pack around $199, with copay programs for eligible patients; coverage varies by plan. citeturn1search5turn0search3turn1news13

SLIT tablets: why “auto‑injectable epinephrine” still matters

FDA‑approved SLIT tablets (examples: GRASTEK for certain grass pollens; RAGWITEK for ragweed; ODACTRA for dust mite) carry a boxed warning for anaphylaxis. Their U.S. labels require: (1) the first dose be taken under medical supervision with 30‑minute observation, and (2) prescribing an auto‑injectable epinephrine device for home use with instruction and training. These labels currently specify “auto‑injectable epinephrine,” not “epinephrine” in general; patients should follow the tablet label and their prescriber’s instructions.

Practical implications

• If you are prescribed SLIT tablets, plan to keep an FDA‑approved auto‑injector available per label, even though neffy exists. Discuss any desire to use neffy with your prescribing clinician; do not change your emergency plan without medical guidance.

SLIT drops (custom, off‑label in the U.S.): safety context

Custom SLIT drops for environmental allergies are widely used off‑label in the U.S. and are associated with a very low rate of severe systemic reactions relative to injection immunotherapy; published and practice data suggest the risk of anaphylaxis with SLIT drops is extremely low, though not zero. Wyndly uses physician‑directed protocols and monitors patients; many practices do not require patients on drops to carry epinephrine, but this is individualized. Ask your doctor what’s appropriate for you.

Where Wyndly fits—and where it doesn’t

• What we do: Wyndly treats environmental allergies (e.g., pollen, dust mite, pet dander, molds) using personalized SLIT (drops and, when appropriate, tablets) under physician supervision. See our program overview and doctor‑supervised SLIT details.

• What we don’t do: We do not treat food allergies or provide emergency anaphylaxis medications; we do not dispense or prescribe epinephrine products (including neffy). Patients at risk for anaphylaxis should maintain an emergency action plan and obtain epinephrine from their allergist or primary care clinician.

Quick reference: neffy vs. SLIT‑related needs

Topic	Neffy (epinephrine nasal spray)	SLIT tablets (FDA‑approved)	SLIT drops (custom, off‑label)
Purpose	Emergency treatment of anaphylaxis	Long‑term desensitization	Long‑term desensitization
Route	Intranasal single‑dose device	Sublingual tablet	Sublingual allergen drops
Age/weight	≥4 years; 15–<30 kg: 1 mg; ≥30 kg: 2 mg	Ages depend on product (see PI)	Clinical practice protocols
First‑dose supervision	Not applicable	Required, observe ≥30 minutes	Typically not required; practice‑dependent
Epinephrine requirement	N/A (neffy is epinephrine)	Label requires prescribing an auto‑injectable epinephrine device	Usually not required; clinician discretion
Second dose timing	May repeat starting 5 minutes if no improvement/worsening	Not applicable	Not applicable
After use	Call 911/seek emergency care	Continue per plan	Continue per plan

Sources: FDA approval/labeling for neffy; SLIT tablet prescribing information.

FAQs

• Is neffy “as good as” an auto‑injector? FDA approved neffy after studies showed comparable epinephrine blood levels and cardiovascular effects to auto‑injectors; however, individual clinical circumstances (e.g., nasal disease) and product labeling for other therapies (e.g., SLIT tablets) may still necessitate carrying an auto‑injector. Follow your clinician’s advice.

• How soon should I repeat a neffy dose if needed? Labeling permits a second dose starting 5 minutes after the first if there’s no improvement or symptoms worsen—then seek emergency care. Carry two devices.

• Is neffy covered by insurance? Access continues to evolve. Example: Express Scripts added neffy to commercial formularies in November 2024; manufacturers also offer copay programs. Check your specific plan.

Related Wyndly resources

• SLIT, safety, and how our care works: Allergy immunotherapy (SLIT) overview; Are allergy drops safe?; Allergy shots vs. sublingual immunotherapy; What is sublingual immunotherapy for allergies?.

---

Last reviewed: November 1, 2025. Regulatory details (e.g., indications, age/weight limits) reflect FDA communications on August 9, 2024 (initial approval) and March 7, 2025 (pediatric expansion to 15–<30 kg).